chemodynamic therapy / GSH Cancer Research Results

CDT, chemodynamic therapy: Click to Expand ⟱
Features:
Chemodynamic therapy (CDT) is an emerging cancer treatment strategy that leverages the unique tumor microenvironment to generate toxic reactive oxygen species (ROS) in situ. Unlike conventional chemotherapy, which often has systemic toxicity, CDT aims to induce localized cell death through chemical reactions that occur preferentially within tumors.

How Chemodynamic Therapy Works
1.Tumor Microenvironment Exploitation:
Tumors often exhibit a higher concentration of hydrogen peroxide (H₂O₂), an acidic environment, and elevated levels of certain metal ions (e.g., Fe²⁺). CDT exploits these characteristics to trigger chemical reactions selectively within the tumor.

2.Fenton and Fenton-like Reactions:
At the heart of CDT is the Fenton reaction, where transition metal ions (typically iron) catalyze the decomposition of H₂O₂ to generate hydroxyl radicals (•OH). These radicals are highly reactive and induce oxidative damage to cellular components like lipids, proteins, and DNA. The basic Fenton reaction:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻

3.Minimizing Systemic Toxicity:
Because the reaction heavily depends on the tumor’s specific conditions (e.g., acidic pH and high H₂O₂ levels), CDT can achieve a localized therapeutic effect with reduced harm to healthy tissues.

4.Nanomaterials as Catalysts:
Often, CDT is facilitated by nanoparticle catalysts (e.g., iron oxide, copper-based, or other metal-based nanoparticles) that can be engineered to accumulate in tumor tissues. These nanomaterials not only provide a catalytic surface but can also be modified for improved tumor targeting and controlled release.

Chemodynamic therapy provides a promising approach for cancer treatment by using the tumor’s inherent properties—like high H₂O₂ and acidic pH—to catalyze ROS generation via Fenton reactions. By targeting pathways related to oxidative stress, iron metabolism, redox balance, and cell survival signaling, CDT aims to selectively induce cancer cell death while reducing collateral damage to normal tissues.

Target Pathways in Chemodynamic Therapy
Oxidative Stress Pathways:ROS Generation, Mitochondrial Dysfunction, MMP, DNA Damage
Iron Homeostasis and Metabolism: Fenton Reaction Catalysis: The availability of Fe²⁺ is crucial for the Fenton reaction, making the iron uptake pathways a critical target.
MAPK/ERK Pathway, PI3K/Akt Pathway: increased ROS can inhibit pro-survival pathways like PI3K/Akt, tipping the balance towards cell death.
Glutathione (GSH) Depletion:
Nrf2 Pathway Inhibition: Inhibiting Nrf2 can make cancer cells more susceptible to ROS.
Acidic Tumor Microenvironment: Many nanomaterials used in CDT are designed to be activated in acidic conditions, ensuring that the Fenton reaction proceeds efficiently within the tumor milieu.
Autophagic: Increased ROS levels can also affect autophagy—a cellular “self-eating” process

Chemodynamic therapy — Chemodynamic therapy is a tumor-microenvironment-activated anticancer modality that uses transition-metal catalysts, usually delivered as nanomaterials or metal-containing platforms, to convert endogenous hydrogen peroxide into highly cytotoxic radical species through Fenton or Fenton-like chemistry. It is best classified as a redox-based nanotherapeutic and oxidative-stress amplification strategy rather than a single drug. The standard abbreviation is CDT. Its conceptual origin is tumor-selective exploitation of relatively higher intratumoral H₂O₂, acidic or mildly acidic compartments, and abnormal redox buffering, often with iron, copper, manganese, cobalt, or related catalytic systems. In practice, modern CDT is usually formulated as a combination platform that also depletes glutathione, perturbs ferroptosis control, relieves hypoxia for partner modalities, or couples with chemo-, photo-, sono-, radio-, or immunotherapy. Current oncology use remains largely experimental and formulation-dependent rather than standardized clinical practice.

Primary mechanisms (ranked):

  1. Fenton or Fenton-like catalytic conversion of H₂O₂ into hydroxyl radicals and related oxidative species within tumor tissue
  2. Intratumoral thiol depletion, especially glutathione depletion, to prevent radical quenching and amplify oxidative damage
  3. Lipid peroxidation amplification with ferroptotic contribution in iron-responsive systems
  4. Mitochondrial oxidative injury with membrane potential collapse and bioenergetic failure
  5. Oxidative DNA, protein, and membrane damage leading to apoptosis, necrosis, or mixed programmed cell death
  6. Hypoxia modulation or local O₂ generation that can improve partner therapies such as PDT or radiotherapy in some platforms
  7. Secondary suppression or overload of redox-adaptive pathways such as NRF2-related defense programs, depending on formulation and tumor context
  8. In selected copper-rich systems, cuproptotic or cuproptosis-like stress can contribute as a secondary mechanism rather than a universal CDT feature

Bioavailability / PK relevance: CDT is delivery-constrained. Most clinically relevant constructs are nanoparticles, metal-organic frameworks, or catalytic nanoplatforms whose efficacy depends on tumor deposition, metal release, intratumoral retention, catalytic accessibility, and eventual clearance. PK is therefore platform-specific rather than modality-wide. Reticuloendothelial uptake, liver/spleen sequestration, incomplete tumor penetration, and long-term metal or carrier biocompatibility remain central translational constraints.

In-vitro vs systemic exposure relevance: CDT is not primarily a fixed systemic concentration modality; it is a local catalytic process that depends on H₂O₂ availability, acidity, redox buffering, and catalyst localization. Many in-vitro studies likely overstate efficiency because cell systems often provide more favorable catalyst contact, higher effective dosing, or simplified redox conditions than heterogeneous in-vivo tumors. A major translational issue is that endogenous tumor H₂O₂ and acidity are often insufficient for robust Fenton chemistry unless the platform also boosts H₂O₂ production, depletes GSH, adds heat, or combines with another modality.

Clinical evidence status: Predominantly preclinical. The field is supported by extensive mechanistic and animal literature, with growing translational interest and at least early first-in-human activity reported for an iron-loaded carbon nanoparticle platform in advanced solid tumors, but CDT is not an established standard oncology treatment and no specific CDT platform appears to have broad regulatory approval as a named cancer therapy at present.

Chemodynamic Therapy Mechanistic Axes

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Fenton and Fenton-like radical catalysis ROS ↑↑; •OH ↑; oxidative burden ↑ ROS ↑ only if off-target catalyst delivery occurs P/R Core tumor killing chemistry Central CDT axis. Requires accessible catalyst plus endogenous or co-generated H₂O₂. Usually strongest with Fe, Cu, Mn, Co, or engineered catalytic centers.
2 Glutathione redox buffering GSH ↓; radical quenching ↓; redox collapse ↑ ↔ or GSH ↓ if exposure is systemic R/G Amplifies CDT efficiency High tumor GSH is a major resistance axis. Many platforms intentionally consume GSH or block thiol-dependent detoxification.
3 Lipid peroxidation and ferroptosis axis Lipid ROS ↑; ferroptosis ↑ (context-dependent) ↔ or lipid ROS ↑ if poorly selective R/G Membrane-destructive death signaling Especially relevant in iron-responsive systems or when SLC7A11-GPX4 protection is weakened. Not universal, but often mechanistically meaningful.
4 Mitochondrial ROS increase and MPTP dysfunction Mitochondrial ROS ↑; MMP ↓; mitochondrial injury ↑ ↔ or mitochondrial stress ↑ with off-target exposure R/G Bioenergetic collapse Common downstream integrator of CDT injury. Promotes apoptosis, necrosis, and redox amplification loops.
5 DNA damage DNAdam ↑; strand damage ↑; replication stress ↑ ↔ or DNAdam ↑ if normal tissue is exposed R/G Loss of proliferative viability Hydroxyl radicals are highly damaging but short-ranged, so localization is critical for selectivity.
6 NRF2 and antioxidant defense adaptation NRF2 defense ↔/↑ initially; functional overwhelm or inhibition can sensitize CDT NRF2 ↑ may be protective G Determinant of resistance versus sensitivity NRF2 is not always directly inhibited by CDT, but antioxidant escape strongly shapes response. Combination designs often target this indirectly through GSH and thiol depletion.
7 Hypoxia modulation and therapy sensitization Hypoxia ↓ (model-dependent); ChemoSen ↑; RadioS ↑ ↔ R/G Adjunct synergy Some CDT systems generate O₂ or reduce redox-mediated resistance, improving PDT, radiotherapy, or chemotherapy rather than acting as pure monotherapy.
8 Cuproptosis or copper-driven proteotoxic stress Cupro ↑ (copper systems only) ↔ or toxicity ↑ if copper exposure is off-target R/G Secondary programmed death route Relevant to copper-based CDT platforms, but not a defining feature of all CDT.
9 PI3K-Akt MAPK stress-survival signaling Pro-survival signaling ↓ or stress signaling dysregulated ↔ G Bias toward death over recovery Usually downstream or secondary to oxidative overload rather than the primary initiating mechanism.
10 Clinical Translation Constraint Tumor H₂O₂ often insufficient; acidity often suboptimal; heterogeneity ↑; penetration limited Potential metal and carrier toxicity if biodistribution is unfavorable G Limits real-world efficacy Major barriers are catalyst delivery, intratumoral heterogeneity, RES uptake, long-term clearance, formulation reproducibility, and dependence on combination engineering.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.
Scientific Papers found: Click to Expand⟱
5974- CDT,    Chemodynamic nanomaterials for cancer theranostics
- Review, Var, NA
Fenton↑, ROS↑, RadioS↑, other↑, GSH↓, GPx4↓, ChemoSen↑, sonoS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   GPx4↓, 1,   GSH↓, 1,   ROS↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   sonoS↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   RadioS↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GSH, Glutathione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:280  Target#:137  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page